Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
- Celgene Secures Exclusive Options to Three Immatics TCR-T Targets
- Immatics to Receive $75 Million Upfront Payment and May Be Eligible for Future Opt-in Exercise, Milestone and Royalty Payments
- Immatics Retains Options to Co-Develop or Co-Fund Certain Licensed Products
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.